Terms: = Breast cancer AND KMT2A, TRX1, 4297, MLL, ENSG00000118058, MLL/GAS7, HTRX1, HRX, ALL-1, MLL1A, CXXC7 AND Treatment
48 results:
1. Menin-mll1 Interaction Small Molecule Inhibitors: A Potential Therapeutic Strategy for Leukemia and cancers.
Shi Q; Xu M; Kang Z; Zhang M; Luo Y
Molecules; 2023 Mar; 28(7):. PubMed ID: 37049787
[TBL] [Abstract] [Full Text] [Related]
2. MiR-143-3p Increases the Radiosensitivity of breast cancer Cells Through FGF1.
Wang D; Wang C; Sun L; Lu X; Shi J; Chen J; Zhang X
Cell Mol Biol (Noisy-le-grand); 2022 Feb; 67(5):256-262. PubMed ID: 35818245
[TBL] [Abstract] [Full Text] [Related]
3. Menin‑mll inhibitors induce ferroptosis and enhance the anti‑proliferative activity of auranofin in several types of cancer cells.
Kato I; Kasukabe T; Kumakura S
Int J Oncol; 2020 Oct; 57(4):1057-1071. PubMed ID: 32945449
[TBL] [Abstract] [Full Text] [Related]
4. TXNIP induces growth arrest and enhances ABT263-induced apoptosis in mixed-lineage leukemia-rearranged acute myeloid leukemia cells.
Noura M; Matsuo H; Koyama A; Adachi S; Masutani H
FEBS Open Bio; 2020 Aug; 10(8):1532-1541. PubMed ID: 32511893
[TBL] [Abstract] [Full Text] [Related]
5. PARP goes the weasel! Emerging role of PARP inhibitors in acute leukemias.
Fritz C; Portwood SM; Przespolewski A; Wang ES
Blood Rev; 2021 Jan; 45():100696. PubMed ID: 32482307
[TBL] [Abstract] [Full Text] [Related]
6. Histone methyltransferases regulate the transcriptional expression of ERα and the proliferation of tamoxifen-resistant breast cancer cells.
Kim SS; Lee MH; Lee MO
Breast Cancer Res Treat; 2020 Feb; 180(1):45-54. PubMed ID: 31897900
[TBL] [Abstract] [Full Text] [Related]
7. DOT1L: a key target in normal chromatin remodelling and in mixed-lineage leukaemia treatment.
Sarno F; Nebbioso A; Altucci L
Epigenetics; 2020 May; 15(5):439-453. PubMed ID: 31790636
[TBL] [Abstract] [Full Text] [Related]
8. Genotoxic stress-triggered β-catenin/JDP2/PRMT5 complex facilitates reestablishing glutathione homeostasis.
Cao L; Wu G; Zhu J; Tan Z; Shi D; Wu X; Tang M; Li Z; Hu Y; Zhang S; Yu R; Mo S; Wu J; Song E; Li M; Song L; Li J
Nat Commun; 2019 Aug; 10(1):3761. PubMed ID: 31434880
[TBL] [Abstract] [Full Text] [Related]
9. Cytogenomic characterization of double minute heterogeneity in therapy related acute myeloid leukemia.
Koduru P; Chen W; Haley B; Ho K; Oliver D; Wilson K
Cancer Genet; 2019 Oct; 238():69-75. PubMed ID: 31425928
[TBL] [Abstract] [Full Text] [Related]
10. breast Tuberculosis in Women: A Systematic Review.
Quaglio G; Pizzol D; Isaakidis P; Bortolani A; Tognon F; Marotta C; Di Gennaro F; Putoto G; Olliaro PL
Am J Trop Med Hyg; 2019 Jul; 101(1):12-21. PubMed ID: 31115305
[TBL] [Abstract] [Full Text] [Related]
11. Mapping Bromodomains in breast cancer and association with clinical outcome.
Pérez-Pena J; Páez R; Nieto-Jiménez C; Sánchez VC; Galan-Moya EM; Pandiella A; Győrffy B; Ocana A
Sci Rep; 2019 Apr; 9(1):5734. PubMed ID: 30952871
[TBL] [Abstract] [Full Text] [Related]
12. Diverse roles of the E2/E3 hybrid enzyme UBE2O in the regulation of protein ubiquitination, cellular functions, and disease onset.
Ullah K; Zubia E; Narayan M; Yang J; Xu G
FEBS J; 2019 Jun; 286(11):2018-2034. PubMed ID: 30468556
[TBL] [Abstract] [Full Text] [Related]
13. Clinical Next-Generation Sequencing for Precision Oncology in Rare cancers.
Groisberg R; Hong DS; Roszik J; Janku F; Tsimberidou AM; Javle M; Meric-Bernstam F; Subbiah V
Mol Cancer Ther; 2018 Jul; 17(7):1595-1601. PubMed ID: 29654067
[TBL] [Abstract] [Full Text] [Related]
14. Palbociclib can overcome mutations in cyclin dependent kinase 6 that break hydrogen bonds between the drug and the protein.
Hernandez Maganhi S; Jensen P; Caracelli I; Zukerman Schpector J; Fröhling S; Friedman R
Protein Sci; 2017 Apr; 26(4):870-879. PubMed ID: 28168755
[TBL] [Abstract] [Full Text] [Related]
15. Poly (ADP-ribose) polymerase inhibitors selectively induce cytotoxicity in TCF3-HLF-positive leukemic cells.
Piao J; Takai S; Kamiya T; Inukai T; Sugita K; Ohyashiki K; Delia D; Masutani M; Mizutani S; Takagi M
Cancer Lett; 2017 Feb; 386():131-140. PubMed ID: 27894958
[TBL] [Abstract] [Full Text] [Related]
16. Low-dose salinomycin induces anti-leukemic responses in AML and mll.
Roulston GD; Burt CL; Kettyle LM; Matchett KB; Keenan HL; Mulgrew NM; Ramsey JM; Dougan C; McKiernan J; Grishagin IV; Mills KI; Thompson A
Oncotarget; 2016 Nov; 7(45):73448-73461. PubMed ID: 27612428
[TBL] [Abstract] [Full Text] [Related]
17. Cambogin exerts anti-proliferative and pro-apoptotic effects on breast adenocarcinoma through the induction of NADPH oxidase 1 and the alteration of mitochondrial morphology and dynamics.
Shen K; Lu F; Xie J; Wu M; Cai B; Liu Y; Zhang H; Tan H; Pan Y; Xu H
Oncotarget; 2016 Aug; 7(31):50596-50611. PubMed ID: 27418140
[TBL] [Abstract] [Full Text] [Related]
18. CLDN6-induced apoptosis via regulating ASK1-p38/JNK signaling in breast cancer MCF-7 cells.
Guo Y; Lin D; Zhang M; Zhang X; Li Y; Yang R; Lu Y; Jin X; Yang M; Wang M; Zhao S; Quan C
Int J Oncol; 2016 Jun; 48(6):2435-44. PubMed ID: 27035750
[TBL] [Abstract] [Full Text] [Related]
19. The thioredoxin system in breast cancer cell invasion and migration.
Bhatia M; McGrath KL; Di Trapani G; Charoentong P; Shah F; King MM; Clarke FM; Tonissen KF
Redox Biol; 2016 Aug; 8():68-78. PubMed ID: 26760912
[TBL] [Abstract] [Full Text] [Related]
20. Combating trastuzumab resistance by targeting thioredoxin-1/PTEN interaction.
Sadeghirizi A; Yazdanparast R; Aghazadeh S
Tumour Biol; 2016 May; 37(5):6737-47. PubMed ID: 26662109
[TBL] [Abstract] [Full Text] [Related]
[Next]
